Innate Pharma S.A.
IPHYF
$1.50
$0.139.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -23.02% | -19.80% | 9.12% | 16.45% | -163.39% |
| Total Depreciation and Amortization | -13.23% | -15.50% | -34.72% | -39.99% | -41.66% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 62.60% | 58.34% | 6,211.28% | 5,699.09% | 333.67% |
| Change in Net Operating Assets | -69.21% | -70.01% | -156.20% | -151.66% | 191.73% |
| Cash from Operations | -137.40% | -131.18% | -1,182.35% | -1,095.06% | 53.38% |
| Capital Expenditure | 17.19% | 19.36% | 78.40% | 80.14% | -154.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -94.82% | -94.96% | 510.25% | 461.03% | -60.07% |
| Cash from Investing | -95.84% | -95.95% | 688.98% | 625.34% | -60.79% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 1.35% | 1.35% | -0.81% | -0.81% | -488.79% |
| Issuance of Common Stock | -98.27% | -98.27% | 15,955.91% | 15,955.91% | 5,931.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -186.25% | -178.74% | 355.28% | 334.69% | -131.14% |
| Foreign Exchange rate Adjustments | 130.79% | 130.01% | 519.31% | 485.45% | -290.49% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -678.45% | -658.06% | -2,072.64% | -1,897.07% | -339.72% |